Canton Biologics is a molecule biopharmaceutical CDMO founded in Guangzhou in 2016 by Dr. Xiao Shen. The company provides end-to-end services from biopharmaceutical CMC development to commercial production and global clinical supply. It has capabilities in high-yield cell line development, complex protein expression, and international manufacturing. Canton has made advancements in its IgM molecule expression platform, expression host cells, high-density cell culture, new formulations, and analytical methodologies. The company raised over 300M Yuan in a Series C financing and plans to use the proceeds to expand R&D in novel biotechnologies, scale commercial production capabilities, and expand its global strategic presence.

Total raised

$41M

Funding rounds

1

Latest round

Series C

Latest activity

Sep 2023